Abbott Laboratories (ABT) Holdings Trimmed by Quantitative Systematic Strategies LLC

Quantitative Systematic Strategies LLC lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 11.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,091 shares of the healthcare product maker’s stock after selling 3,972 shares during the period. Quantitative Systematic Strategies LLC’s holdings in Abbott Laboratories were worth $1,606,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ABT. Heritage Trust Co increased its position in shares of Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after acquiring an additional 200 shares in the last quarter. Winfield Associates Inc. increased its position in shares of Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after acquiring an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. increased its position in shares of Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after acquiring an additional 370 shares in the last quarter. JFS Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock worth $131,000 after acquiring an additional 2,094 shares in the last quarter. Finally, Motco increased its position in shares of Abbott Laboratories by 213.7% in the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 1,962 shares in the last quarter. 71.32% of the stock is currently owned by institutional investors.

ABT has been the subject of several recent research reports. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Stifel Nicolaus increased their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets reissued a “hold” rating and issued a $53.00 price objective on shares of Abbott Laboratories in a research report on Friday, September 1st. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $57.56.

Shares of Abbott Laboratories (NYSE ABT) opened at $55.50 on Friday. The firm has a market cap of $96,603.35, a price-to-earnings ratio of 23.03, a P/E/G ratio of 2.08 and a beta of 1.06. Abbott Laboratories has a fifty-two week low of $37.90 and a fifty-two week high of $56.69. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. equities analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 2.02%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.

In related news, insider Sharon J. Bracken sold 2,188 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $56.12, for a total transaction of $122,790.56. Following the completion of the sale, the insider now directly owns 25,618 shares of the company’s stock, valued at approximately $1,437,682.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the firm’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the sale, the insider now directly owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 616,332 shares of company stock valued at $33,579,226. Company insiders own 0.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/12/17/abbott-laboratories-abt-holdings-trimmed-by-quantitative-systematic-strategies-llc.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply